A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Inclusion Criteria:

All participants:

• Male or nonpregnant, nonbreastfeeding female participants.

For PsO Participants:

• Present with chronic PsO based on a confirmed diagnosis of chronic PsO vulgaris forat least 6 months prior to baseline

• Have ≥10% Body Surface Area (BSA) of psoriasis at screening (Visit 1) and baseline

• Have both an static Physician's Global Assessment (sPGA) score of ≥3 and PsoriasisArea and Severity Index (PASI) score ≥12 at screening and baseline

For PsA Participants

• Have a diagnosis of active PsA for at least 6 months (based on a detailed medicalhistory provided by the patient, and a physical exam by the Study Investigator,and/or other evidence such as that provided by joint x-rays, that establishes ahistory consistent with a diagnosis of active PsA of at least 6 months' duration)and currently meet the Classification for PsA (CASPAR) criteria.

• Have active PsA defined as the presence of at least 3/68 tender and at least 3/66swollen joints, as determined by the Tender and Swollen Joint Count Assessment Format screening and baseline.

• Presence of active PsO or a documented history of psoriasis.

Exclusion Criteria:

• Have previously completed or withdrawn from this study, participated in any otherstudy with ixekizumab, or have participated in any study investigating other IL-17antagonists.

• Have a history of drug-induced PsO.

• Have a known allergy or hypersensitivity to any biologic therapy that would pose anunacceptable risk to the patient if participating in this study.

• Had any major surgery within 8 weeks prior to baseline (Week 0; Visit 2), or willrequire such during the study that, in the opinion of the investigator inconsultation with Lilly or its designee, would pose an unacceptable risk to theparticipant

• Have diagnosis or history of malignant disease within the 5 years prior to baseline

• Have any other active or recent infection within 4 weeks of baseline

For PsO Participants:

• Have received systemic non-biologic PsO therapy (within 4 weeks prior to baseline)

• Have pustular, erythrodermic, and/or guttate forms of PsO

• Had a clinically significant flare of PsO during the 12 weeks prior to baseline (Week 0).

• Have allergy to rubber or latex.

For PsA Participants:

• Have used conventional synthetic disease-modifying antirheumatic drug (csDMARDs)other than methotrexate (MTX), leflunomide, sulfasalazine, or cyclosporine in the 8weeks prior to baseline

• Have received treatment with interleukin (IL)17 or IL-12/23 targeted Mab therapy

• Are currently receiving treatment with any biologic or small molecule therapy forPsA or PsO, including investigational therapies (such as, but not limited to, atumor necrosis factor inhibitor (TNFi), IL-1 receptor antagonists, IL-6 inhibitor,anti-IL12/23p40, T cell or B cell targeted therapies, phosphodiesterase (PDE) 4inhibitors, or Janus Kinase (JAK) inhibitors), or have received denosumab.

• Have had surgical treatment of a joint within 8 weeks prior to baseline or willrequire such up to Week 24.